On the eve of Boston Biotech Week, a report was released by MassBio that claimed 48% of all biotech investment in 2017 was accounted for by Massachusetts-based companies.
The market and economy have been strong this year, as well as the tax changes which are helping to drive investments and M&A activity and the momentum of deal flow.